Table 2.
Cox’s proportional hazards model for predictors of progression-free survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age ≥ 65 years (vs. < 65 years) | 1.163 | 0.742-1.824 | 0.510 | |||
| Male gender (vs. female) | 0.966 | 0.522-1.787 | 0.911 | |||
| Viral etiology (vs. others) | 0.793 | 0.463-1.357 | 0.397 | |||
| Child-Pugh A (vs. B) | 0.639 | 0.232-1.757 | 0.385 | |||
| ALBI grade I (vs. II/III) | 0.693 | 0.442-0.888 | 0.041 | 0.725 | 0.504-0.895 | 0.040 |
| Macrovascular invasion (vs. no) | 1.681 | 0.961-2.664 | 0.077 | |||
| Extrahepatic distant metastasis (vs. no) | 0.676 | 0.432-1.058 | 0.087 | |||
| BCLC stage B (vs. C) | 1.243 | 0.764-2.023 | 0.381 | |||
| AFP ≥ 400 ng/ml (vs. < 400) | 1.338 | 0.847-2.113 | 0.092 | |||
| Combination therapy (vs. no) | 0.562 | 0.327-0.967 | 0.037 | 0.734 | 0.380-1.421 | 0.359 |
| SII < 330 (vs. ≥ 330) | 0.255 | 0.119-0.543 | < 0.001 | 0.341 | 0.141-0.828 | 0.017 |
| AE (vs. no) | 1.003 | 0.623-1.614 | 0.991 | |||
Abbreviations: AE, adverse effect; AFP, alpha-fetoprotein; ALBI, Albumin-Bilirubin; BCLC, Barcelona Clinic Liver Cancer; SII, systemic inflammatory index.